Should GLP-1 Drugs Be Used Earlier in Young People with Type 2 Diabetes? | Research

The takeaway

Youth-onset type 2 diabetes progresses aggressively, and early use of GLP-1 receptor agonists and SGLT-2 inhibitors may prevent complications better than traditional metformin and insulin therapy.

Most develop complications
Within 13 years, most youth T2D patients on standard therapy develop at least one diabetes complication

What the researchers found

Standard metformin+insulin therapy fails to prevent complications in most youth T2D patients (cumulative incidence of at least one complication within 13 years). GLP-1RAs and SGLT-2is offer β-cell preservation and weight management benefits that could improve long-term outcomes if used early.

Why it matters

Youth-onset T2D is a growing epidemic with devastating long-term consequences. If GLP-1 drugs can preserve beta-cell function when started early, they could prevent decades of diabetes complications in young patients.

How the study worked

Narrative review of current evidence for GLP-1 RAs and SGLT-2 inhibitors in youth-onset T2D, focusing on early disease intervention within 1-2 years of diagnosis.

What this study cannot tell us

Limited long-term data for GLP-1RAs in youth populations. Most evidence extrapolated from adult trials. Optimal timing and combination strategies not yet defined.

How to read the evidence

Narrative review making a case for early intervention. Based on strong rationale and emerging evidence, but long-term youth-specific RCT data are still needed.

When this study was published

Published in 2025, reflecting the newest treatment options available for youth T2D.

The bigger picture

The shift from reactive to proactive diabetes management in young people represents a paradigm change. GLP-1 peptide drugs could transform outcomes for a generation facing lifelong diabetes.

Questions still open

Would starting GLP-1 therapy at diagnosis prevent β-cell failure in youth T2D?
Should GLP-1RAs replace metformin as first-line therapy in youth-onset T2D?
What are the long-term safety profiles of GLP-1 drugs started in adolescence?

Common questions

Why is type 2 diabetes worse in young people?

Youth-onset T2D progresses faster than adult-onset disease. Beta cells (the cells that make insulin) fail more quickly, and most young patients develop complications like kidney disease, eye damage, or nerve problems within 13 years despite standard treatment.

Could GLP-1 drugs help young people with diabetes?

Yes, GLP-1 drugs may help preserve the insulin-producing cells that fail in T2D, while also promoting weight loss. This review argues they should be started early—within 1-2 years of diagnosis—rather than waiting for other treatments to fail.

Read the original research

Pros and Cons of Early Treatment with GLP-1 Receptor Agonist and SGLT-2 Inhibitors for Youth with Type 2 Diabetes: A Narrative Review.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 17(1), 41-54

View on PubMed ↗Publisher’s paper ↗

Citation

DeLacey, Sean E; Dieguez, Abigayil C; Bensignor, Megan O. (2026). Pros and Cons of Early Treatment with GLP-1 Receptor Agonist and SGLT-2 Inhibitors for Youth with Type 2 Diabetes: A Narrative Review.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 17(1), 41-54. https://doi.org/10.1007/s13300-025-01823-7